Hepalink-Backed HighTide Bets On NASH For Global Markets

 
• By Brian Yang

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.

Emerging Company Profile Regular column feature image Version 2
HighTide Obtains Fast-Track Designations For NASH and PSC Compounds

More from China

More from Focus On Asia